Voyager Therapeutics Inc (OQ:VYGR)

Business Focus: Biotechnology & Medical Research

Apr 16, 2024 07:00 am ET
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development...
Mar 26, 2024 04:01 pm ET
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with Toby Ferguson, M.D., Ph.D. that, among other things, provides for the grant to Dr....
Mar 13, 2024 07:00 am ET
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Toby Ferguson, M.D., Ph.D., as Chief Medical Officer (CMO), effective March 25, 2024. Ferguson is a...
Feb 28, 2024 04:01 pm ET
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today reported fourth quarter and full year 2023 financial and operating results. “As of December 31, 2023, Voyager had approximately...
Feb 26, 2024 07:00 am ET
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development...
Feb 21, 2024 07:00 am ET
Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2023 financial and operating results after market close on Wednesday, February 28, 2024....
Feb 20, 2024 07:00 am ET
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research
Data to be presented at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2024) - LEXINGTON, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR),...
Feb 07, 2024 07:00 am ET
Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Chief Financial Officer Peter Pfreundschuh will present at the Oppenheimer Life Sciences Conference on February...
Jan 04, 2024 10:45 pm ET
Voyager Therapeutics Announces Pricing of Public Offering
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the pricing of an underwritten public offering of 7,777,778 shares of its common stock at a public offering price of...
Jan 04, 2024 04:14 pm ET
Voyager Therapeutics Announces Proposed Public Offering
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock (or pre-funded...
Jan 03, 2024 07:00 am ET
Voyager Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Chief Executive Officer Alfred W. Sandrock, Jr., M.D., Ph.D., will present at the 42nd Annual J.P. Morgan...
Jan 02, 2024 08:31 am ET
Thinking about buying stock in Voyager Therapeutics, Fusion Pharmaceuticals, AT&T, Argo Blockchain, or China Green Agriculture?
NEW YORK, Jan. 2, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VYGR, FUSN, T, ARBK, and CGA.
Jan 02, 2024 07:00 am ET
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE:...
Dec 06, 2023 07:00 am ET
Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that it has selected a lead development candidate for its superoxide dismutase 1 (SOD1)-mutated...
Nov 06, 2023 04:01 pm ET
Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported third quarter 2023 financial and operating results. “Voyager continues to advance our...
Oct 30, 2023 07:00 am ET
Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report third quarter 2023 financial and operating results after market close on Monday,...
Sep 25, 2023 07:00 am ET
Voyager Therapeutics to Present at the Chardan Genetic Medicines Conference
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that Chief Executive Officer Alfred W. Sandrock, Jr., M.D., Ph.D., will present at the Chardan...
Sep 07, 2023 04:01 pm ET
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into employment agreements with three newly-hired employees that, among other things, provide for...
Aug 30, 2023 07:00 am ET
Voyager Therapeutics to Participate in Upcoming Investor Conferences
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that management will participate in the following investor conferences: Wells Fargo Health...
Aug 08, 2023 04:01 pm ET
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into an employment agreement with Beth Shafer, Ph.D., M.A., M.Phil. that, among other things,...
Aug 07, 2023 08:00 am ET
Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Beth Shafer, Ph.D., M.A., M.Phil., as Chief Business Officer (CBO). Shafer...
Aug 03, 2023 07:00 am ET
Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported second quarter 2023 financial and operating results. “The introduction today of Voyager’s...
Aug 02, 2023 07:00 am ET
Voyager Therapeutics to Present at the Canaccord Genuity Growth Conference
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that Chief Scientific Officer Todd Carter, Ph.D., and Chief Financial Officer Peter...
Jul 27, 2023 07:00 am ET
Voyager Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report second quarter 2023 financial and operating results before the market opens on...
Jul 11, 2023 04:01 pm ET
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into employment agreements with Jacquelyn Fahey Sandell and another newly hired employee that,...
Jul 10, 2023 08:00 am ET
Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Jacquelyn Fahey Sandell as Chief Legal Officer (CLO). Fahey Sandell brings...
Jun 01, 2023 07:00 am ET
Voyager Therapeutics to Present at the Jefferies Healthcare Conference
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that CEO Alfred W. Sandrock, Jr., M.D., Ph.D., will present at the Jefferies Healthcare...
May 18, 2023 06:00 am ET
Voyager Therapeutics Presents Robust, Multi-Species Results from Preclinical Studies of IV-Delivered, TRACER™-Generated Novel Capsids at the ASGCT 26th Annual Meeting
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, presented data today validating the ability of novel capsids generated through its TRACER™ capsid discovery...
May 09, 2023 07:00 am ET
Voyager Therapeutics Reports First Quarter 2023 Financial and Operating Results
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported first quarter 2023 financial and operating results. “Voyager started 2023 by securing...
May 09, 2023 06:55 am ET
Voyager Therapeutics Announces Appointment of George Scangos, Ph.D., to Board of Directors
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of George Scangos, Ph.D., to its Board of Directors. Scangos has decades of...
May 02, 2023 04:30 pm ET
Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced seven data presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 26th...
May 02, 2023 07:00 am ET
Voyager Therapeutics Announces First Quarter 2023 Conference Call and Webcast
Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report first quarter 2023 financial and operating results before the market opens on...
Mar 28, 2023 07:00 am ET
Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimer’s Disease and GBA1 Gene Therapy Program for Parkinson’s Disease at the AD/PD™ Conference
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today presented new data from its anti-tau antibody program for Alzheimer’s disease (AD) and from its GBA1 gene...
Mar 07, 2023 07:00 am ET
Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported fourth quarter and full year 2022 financial and operating results. “The past year has been...
Mar 06, 2023 07:00 am ET
Voyager Therapeutics to Receive $25 Million Payment for License of Next-Generation AAV Capsids for Multiple Neurologic Disease Targets
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that Novartis AG (NYSE: NVS) has exercised its options to license novel capsids generated from...
Feb 28, 2023 07:00 am ET
Voyager Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast
Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report fourth quarter and full year 2023 financial and operating results before the...
Feb 09, 2023 07:00 am ET
Voyager Therapeutics to Participate in Upcoming Investor Conferences
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that management will participate in the following investor conferences: SVB Securities Global...
Jan 24, 2023 04:01 pm ET
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into employment agreements with two newly hired employees that, among other things, provide for the...
Jan 09, 2023 07:00 am ET
Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced the formation of a new strategic collaboration to advance multiple gene therapies for the treatment of neurological diseases. The...
Jan 04, 2023 07:00 am ET
Voyager Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that CEO Alfred W. Sandrock, Jr., M.D., Ph.D., will present at the upcoming 41st Annual J.P....
Dec 14, 2022 07:00 am ET
Voyager Therapeutics Appoints Grace E. Colón, Ph.D., to its Board of Directors
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Grace E. Colón, Ph.D., to its Board of Directors. Dr. Colón has more than 25...
Nov 29, 2022 04:01 pm ET
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into an employment agreement with a newly hired employee that, among other things, provides for the...
Nov 08, 2022 07:00 am ET
Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported third quarter 2022 financial and operating results. “The past few months have been...
Nov 01, 2022 07:30 am ET
Voyager Therapeutics Announces Third Quarter 2022 Conference Call and Webcast
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced it will report third quarter 2022 financial and...
Oct 18, 2022 04:01 pm ET
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, has entered into an employment agreement with a newly hired employee...
Oct 11, 2022 07:00 am ET
Voyager Therapeutics Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER™ Generated Capsid Families
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today presented data on the discovery of a novel cell surface receptor identified as a...
Oct 04, 2022 07:00 am ET
Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced that Pfizer, Inc. (NYSE: PFE) has exercised its option...
Oct 03, 2022 07:00 am ET
Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced that it will present three posters at the upcoming 29th...
Sep 27, 2022 07:00 am ET
Voyager Therapeutics to Participate in Upcoming Investor Conferences
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced that management will participate in the following...
Sep 22, 2022 04:01 pm ET
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, has entered into employment agreements with Peter Pfreundschuh and...
Sep 07, 2022 07:30 am ET
Voyager Therapeutics Appoints Peter Pfreundschuh as CFO; Todd Carter, Ph.D., as Chief Scientific Officer; and Trista Morrison as SVP Corporate Affairs
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced the appointment of Peter Pfreundschuh as Chief...
Aug 04, 2022 04:01 pm ET
Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today unveiled its prioritized therapeutic pipeline and reported second...
Aug 03, 2022 11:30 am ET
Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today presented data showing the use of novel antibodies targeting...
Aug 02, 2022 04:01 pm ET
Voyager Therapeutics to Present Second Quarter 2022 Results and Corporate Update
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, will report second quarter 2022 financial and operating results after...
Jul 28, 2022 07:00 am ET
Voyager Therapeutics Appoints Catherine J. Mackey, Ph.D. to its Board of Directors
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced the appointment of Catherine J. Mackey, Ph.D. to its Board of Directors....
May 19, 2022 06:00 am ET
Voyager Therapeutics’ TRACER™ Capsids Demonstrate Enhanced CNS Transduction Across Species; New Preclinical Results Bolster GBA1, Tau, SOD1 ALS Gene Therapy Programs
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today is scheduled to present new preclinical data on a family of AAV9-derived TRACER...
May 16, 2022 06:00 am ET
Voyager Therapeutics to Present Preclinical Data from its Vectorized anti-HER2 Antibody Program and a Novel AAV5-Derived TRACER™ Capsid at the 25th American Society of Gene and Cell Therapy Annual Mee
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today is scheduled to present findings demonstrating preclinical proof-of-concept for...
May 04, 2022 04:01 pm ET
Voyager Therapeutics Reports First Quarter 2022 Financial and Operating Results
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today reported first quarter 2022 financial and operating results. “I’m thrilled to be...
May 03, 2022 07:00 am ET
Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2022 Annual Meeting
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced nine data presentations at the upcoming American Society of...
Mar 22, 2022 07:00 am ET
Voyager Therapeutics Appoints Alfred W. Sandrock, Jr., M.D., Ph.D., as Chief Executive Officer
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced the appointment of Alfred W. Sandrock, Jr., M.D., Ph.D., as chief...
Mar 08, 2022 08:31 am ET
Thinking about buying stock in Voyager Therapeutics, Ion Geophysical, KLX Energy, Deutsche Bank, or Smart Sand?
NEW YORK, March 8, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VYGR, IO, KLXE, DB, and SND.
Mar 08, 2022 06:16 am ET
Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today reported fourth quarter and full year 2021 financial and operating results....
Mar 08, 2022 01:15 am ET
Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to Next-Generation TRACER™ AAV Capsids for Gene Therapy Programs
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced an agreement through which Novartis (NYSE: NVS) may exercise options to...
Feb 10, 2022 07:00 am ET
Voyager Therapeutics to Participate in Upcoming Investor Conferences
Voyager Therapeutics, Inc. (Nasdaq: VYGR) a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) technologies, today announced that it will participate in the following virtual investor...
Feb 03, 2022 07:00 am ET
Alfred W. Sandrock, Jr., M.D., Ph.D. Appointed to Voyager Therapeutics’ Board of Directors and Newly Formed Executive Committee
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) technologies, today announced the appointment of Alfred W. Sandrock, Jr., M.D., Ph.D. to its...
Nov 19, 2021 07:30 am ET
Voyager Therapeutics Announces Positive Preclinical Data from New Vectorized anti-HER2 Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) platform technologies, today will present preclinical data demonstrating that IV dosing of a...
Nov 16, 2021 07:00 am ET
Voyager Therapeutics to Present Preclinical Data from Vectorized Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) platform technologies, today announced it will present preclinical data from its vectorized...
Nov 02, 2021 07:00 am ET
Voyager Therapeutics Reports Third Quarter 2021 Financial and Operating Results
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) technologies, today reported third quarter 2021 financial and operating results. “We’ve...
Oct 20, 2021 08:54 am ET
Voyager Therapeutics Presents Positive Preclinical Data Supporting CNS-Directed GBA1 Gene Therapy at Virtual Congress of the European Society of Gene and Cell Therapy
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) platform technologies, today announced the presentation of preclinical data demonstrating a...
Oct 12, 2021 10:50 am ET
Thinking about buying stock in Progenity, Farmmi, RR Donnelley & Sons, SoFi Technologies, or Voyager Therapeutics?
NEW YORK, Oct. 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PROG, FAMI, RRD, SOFI, and VYGR.
Oct 11, 2021 10:55 am ET
Thinking about buying stock in Farmmi, SoFi Technologies, Sphere 3D, PG&E Corp, or Voyager Therapeutics?
NEW YORK, Oct. 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FAMI, SOFI, ANY, PCG, and VYGR.
Oct 07, 2021 10:45 am ET
Thinking about buying stock in Vinco Ventures, Voyager Therapeutics, Farmmi, ZW Data Action Technologies, or Grom Social Enterprises?
NEW YORK, Oct. 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BBIG, VYGR, FAMI, CNET, and GROM.
Oct 06, 2021 08:30 am ET
Thinking about buying stock in Voyager Therapeutics, Aditxt, Agrify, Progenity, or Amplify Energy?
NEW YORK, Oct. 6, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VYGR, ADTX, AGFY, PROG, and AMPY.
Oct 06, 2021 07:00 am ET
Voyager Therapeutics Announces License Option Agreement with Pfizer for Next-Generation TRACERᵀᴹ AAV Capsids to Enable Neurologic and Cardiovascular Gene Therapy Programs
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) platform technologies, today announced an agreement through which Pfizer Inc (NYSE: PFE) may...
Sep 02, 2021 05:08 pm ET
Voyager Therapeutics to Participate in Upcoming Investor Conferences
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation platform technologies, today announced that it will participate in the following upcoming virtual investor conferences. Wells...
Aug 10, 2021 04:20 pm ET
Voyager Therapeutics to Participate in Upcoming Investor Conferences
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation platform technologies, today announced that it will participate in the following upcoming virtual investor conferences....
Aug 09, 2021 07:00 am ET
Voyager Therapeutics Transforms Pipeline and Increases Investment in Next-Generation TRACER™ AAV Capsid and Vectorized Antibody Platform Technologies
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation platform technologies, today introduced new programs in Huntington’s disease, a monogenic form of ALS (SOD1), spinal muscular...
May 19, 2021 04:01 pm ET
Voyager Therapeutics Announces Strategic Shift and Leadership Transitions
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for serious neurological diseases, today announced key leadership transitions and a strategic shift toward a refocused...
May 12, 2021 07:30 am ET
Voyager Therapeutics Presents New Preclinical Data Showing Reduction of Pathological Tau with Vectorized Anti-Tau Antibody
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for serious neurological diseases today will present new preclinical data characterizing the durable expression and...
May 11, 2021 07:30 am ET
Voyager Therapeutics’ Novel Capsids Demonstrate Robust Delivery Across the Blood Brain Barrier, Widespread CNS Transduction in Non-Human Primates
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for serious neurological diseases, today will present new preclinical data demonstrating high transduction efficiency of...
May 10, 2021 07:30 am ET
Voyager Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for patients suffering from serious neurological diseases, today reported its first quarter 2021 financial results,...
Apr 28, 2021 08:00 am ET
Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy Virtual 2021 Annual Meeting
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced multiple data presentations at the American Society of Gene and Cell...
Apr 26, 2021 08:00 am ET
Voyager Therapeutics Receives FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced the U.S. Food and Drug Administration (FDA) has removed its clinical hold on the...
Mar 24, 2021 10:00 am ET
VYGR Deadline: Bronstein, Gewirtz & Grossman, LLC Notifies Voyager Therapeutics, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: March 24, 2021
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ: VYGR) and certain of its officers, on behalf of...
Mar 21, 2021 02:20 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Voyager Therapeutics, Inc. Investors to Secure Counsel Before Important March 24 Deadline in Securities Class Action – VYGR
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1, 2017 and November 9, 2020, inclusive (the “Class Period”), of the important March 24, 2021...
Mar 18, 2021 10:00 am ET
BTBT, VYGR & AZN Class Actions: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Mar 17, 2021 04:17 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Voyager Therapeutics, Inc. Investors to Secure Counsel Before Important March 24 Deadline in Securities Class Action – VYGR
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1, 2017 and November 9, 2020, inclusive (the “Class Period”), of the important March 24, 2021 lead plaintiff deadline.
Mar 12, 2021 06:00 pm ET
ROSEN, A TOP RANKED LAW FIRM, Encourages Voyager Therapeutics, Inc. Investors with Large Losses to Secure Counsel Before Important March 24 Deadline – VYGR
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1, 2017 and November 9, 2020, inclusive (the “Class Period”), of the important March 24, 2021...
Mar 12, 2021 05:45 pm ET
ROSEN, A TOP RANKED LAW FIRM, Encourages Voyager Therapeutics, Inc. Investors with Large Losses to Secure Counsel Before Important March 24 Deadline – VYGR
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1, 2017 and November 9, 2020, inclusive (the “Class Period”), of the important March 24, 2021...
Mar 03, 2021 04:12 pm ET
VOYAGER THERAPEUTICS, INC.  CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court fo
Wolf Haldenstein Adler Freeman & Herz LLP announces that a announces that a federal securities class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NASDAQ: VYGR) in the United States District Court...
Mar 03, 2021 12:10 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Voyager Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - VYGR
NEW YORK, March 3, 2021 /CNW/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NASDAQ: VYGR) and certain of its officers.  The class action, filed in United States District Court for the Eastern District of New York, and docketed under 21-cv-00381, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Voyager securities between June 1, 2017 and November 9, 2020, both dates inclusive (the "Class Period"), seeking to recover damages caused by
Feb 27, 2021 09:00 am ET
VYGR INVESTOR NOTICE: ROSEN, A LEADING LAW FIRM, Encourages Voyager Therapeutics, Inc. Investors to Secure Counsel Before Important March 24 Deadline – VYGR
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1, 2017 and November 9, 2020, inclusive (the “Class Period”), of the important March 24, 2021...
Feb 25, 2021 04:01 pm ET
Voyager Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases, today reported its fourth quarter and full year 2020 financial...
Feb 25, 2021 12:19 pm ET
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Voyager Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact th
LOS ANGELES, Feb. 25, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ: VYGR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Feb 24, 2021 02:04 pm ET
VYGR Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Voyager Therapeutics, Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ: VYGR) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Voyager securities between June 1, 2017 and November 9, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site:
Feb 23, 2021 07:45 pm ET
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Voyager Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline – VYGR
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1, 2017 and November 9, 2020, inclusive (the “Class Period”), of the important March 24, 2021...
Feb 22, 2021 12:06 pm ET
VOYAGER THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eas
Wolf Haldenstein Adler Freeman & Herz LLP announces that a announces that a federal securities class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NASDAQ: VYGR) in the United States District Court...
Feb 22, 2021 10:48 am ET
VYGR MARCH 24 DEADLINE: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Voyager Therapeutics, Inc. – VYGR
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1, 2017 and November 9, 2020, inclusive (the “Class Period”). To join the class action, go to...
Feb 19, 2021 01:00 pm ET
VYGR ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Voyager Therapeutics, Inc.– VYGR
Pawar Law Group announces a class action lawsuit on behalf of shareholders who purchased shares of Voyager Therapeutics, Inc. (NASDAQ: VYGR) from June 1, 2017 through November 9, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover...
Feb 18, 2021 10:18 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Voyager Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - VYGR
NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NASDAQ: VYGR) and certain of its officers. The class action, filed in United States District Court for the Eastern District of New York, and docketed under 21-cv-00381, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Voyager securities between June 1, 2017 and November 9, 2020, both dates inclusive (the "Class Period"), seeking to recover damages cau
Feb 18, 2021 07:10 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Voyager Therapeutics, Inc. Investors with Large Losses to Secure Counsel Before Important Deadline – VYGR
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1, 2017 and November 9, 2020, inclusive (the “Class Period”), of the important March 24, 2021...
Feb 18, 2021 04:01 pm ET
Voyager Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Participate in Upcoming Investor Conference
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, will report fourth quarter and full year 2020 financial results after market close...
Feb 17, 2021 10:00 am ET
BTBT, VYGR & AZN Class Actions: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Feb 16, 2021 03:05 pm ET
Voyager Therapeutics, Inc. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eas
NEW YORK, Feb. 16, 2021 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NASDAQ: VYGR) in the United States District Court for the Eastern District of New York on behalf of a class consisting of all investors that purchased or otherwise acquired Voyager securities between June 1, 2017 and November 9, 2020, inclusive (the "Class Period").
Feb 16, 2021 11:04 am ET
VYGR DEADLINE: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against  Voyager Therapeutics, Inc. – VYGR
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of   Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1, 2017 and November 9, 2020, inclusive (the “Class Period”). To join the class action, go...
Feb 15, 2021 03:56 pm ET
Shareholder Alert: Robbins LLP Reminds Investors That Voyager Therapeutics, Inc. (VYGR) is Being Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP reminds shareholders that a purchaser of Voyager Therapeutics, Inc. (Nasdaq: VYGR) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between June 1, 2017 and November 9, 2020. Voyager is
Feb 10, 2021 04:27 pm ET
ROSEN, A LEADING AND RANKED FIRM, Encourages Voyager Therapeutics, Inc. Investors with Large Losses to Secure Counsel Before Important Deadline – VYGR
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1, 2017 and November 9, 2020, inclusive (the “Class Period”), of the important March 24, 2021...
Feb 10, 2021 08:00 am ET
Voyager Therapeutics, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Voyager Therapeutics, Inc. (NASDAQ: VYGR) investors that acquired shares between June 1, 2017 and November 9, 2020. Investors have until March 24, 2021...
Feb 09, 2021 03:09 pm ET
Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Voyager Therapeutics, Inc. – VYGR
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1, 2017 and November 9, 2020, inclusive (the “Class Period”). To join the class action, go to...
Feb 07, 2021 01:40 pm ET
BREAKING NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Voyager Therapeutics, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline - VYGR
NEW YORK, Feb. 7, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1, 2017 and November 9, 2020, both dates inclusive (the "Class Period"), of the important March 24, 2021 lead plaintiff deadline.
Feb 05, 2021 06:13 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Voyager Therapeutics, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline – VYGR
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1, 2017 and November 9, 2020, both dates inclusive (the “Class Period”), of the important March 24, 2021 lead plaintiff deadline.
Feb 05, 2021 10:00 am ET
VYGR Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Voyager Therapeutics, Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ: VYGR) and certain of its officers, on behalf of...
Feb 03, 2021 07:30 pm ET
VOYAGER THERAPEUTICS, INC. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court fo
NEW YORK, Feb. 3, 2021 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP  announces that a announces that a federal securities class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NASDAQ: VYGR) in the United States District Court for the Eastern District of New York on behalf of a class consisting of all investors that purchased or otherwise acquired Voyager securities between June 1, 2017 and November 9, 2020, inclusive (the "Class Period").
Feb 03, 2021 02:55 pm ET
VYGR DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Voyager Therapeutics, Inc.– VYGR
Pawar Law Group announces a class action lawsuit on behalf of shareholders who purchased shares of Voyager Therapeutics, Inc. (NASDAQ: VYGR) from June 1, 2017 through November 9, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover...
Feb 03, 2021 11:00 am ET
VYGR Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Voyager Therapeutics, Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ: VYGR) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Voyager securities between June 1, 2017 and November 9, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site:
Feb 02, 2021 04:01 pm ET
Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program
Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced that Neurocrine Biosciences, Inc. (Nasdaq: NBIX) provided notice of termination of the Parkinson’s disease portion of the collaboration agreement, effective August 2, 2021. The Friedreich’s...
Feb 02, 2021 08:00 am ET
Portnoy Law: Lawsuit Filed On Behalf of Voyager Therapeutics, Inc. Investors
​The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ: VYGR) investors that acquired securities between June 1, 2017 and November 9, 2020....
Jan 31, 2021 03:00 pm ET
BREAKING ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Voyager Therapeutics, Inc. Investors with Large Losses to Secure Counsel Before Important Deadline – VYGR
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1, 2017 and November 9, 2020, both dates...
Jan 29, 2021 09:01 pm ET
BREAKING NOTICE: ROSEN, A LEADING LAW FIRM, Encourages Voyager Therapeutics, Inc. Investors with Large Losses to Secure Counsel Before Important Deadline - VYGR
NEW YORK, Jan. 29, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1, 2017 and November 9, 2020, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 24, 2021.
Jan 29, 2021 04:15 pm ET
VOYAGER THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eas
Wolf Haldenstein Adler Freeman & Herz LLP announces that a announces that a federal securities class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NASDAQ: VYGR) in the United States District Court...
Jan 29, 2021 11:46 am ET
Moore Kuehn, PLLC Encourages Investors of VYGR, TILE, or SWI to Contact Law Firm
NEW YORK, Jan. 29, 2021 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating potential claims involving directors and officers regarding possible breaches of fiduciary duties related to whether insiders caused their companies to make false and/or misleading statements and/or failed to disclose, among other things, that:
Jan 29, 2021 11:00 am ET
VYGR Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Voyager Therapeutics, Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ: VYGR) and certain of its officers, on behalf of...
Jan 27, 2021 01:02 pm ET
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Voyager Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact t
LOS ANGELES, Jan. 27, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ: VYGR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jan 26, 2021 01:23 pm ET
Portnoy Law: Lawsuit Filed On Behalf of Voyager Therapeutics, Inc. Investors
​The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ: VYGR) investors that acquired securities between June 1, 2017 and November 9, 2020....
Jan 26, 2021 09:00 am ET
VYGR Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Voyager Therapeutics, Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm
NEW YORK, Jan. 26, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ: VYGR) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Voyager securities between June 1, 2017 and November 9, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/vygr.
Jan 26, 2021 08:30 am ET
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Voyager Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Voyager Therapeutics, Inc. (“Voyager” or “the Company”) (NASDAQ:
Jan 25, 2021 06:03 pm ET
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Voyager Therapeutics, Inc. (VYGR)
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. (“Voyager” or the “Company”) (NASDAQ: VYGR) in the United States District Court for the Eastern District of New York on behalf of...
Jan 25, 2021 02:19 pm ET
Shareholder Alert: Robbins LLP Announces That Voyager Therapeutics, Inc. (VYGR) is Being Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP announces that a purchaser of Voyager Therapeutics, Inc. (Nasdaq: VYGR) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between June 1, 2017 and November 9, 2020. Voyager is a clinical-stage
Jan 25, 2021 01:49 pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Voyager Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact th
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Voyager Therapeutics, Inc. (“Voyager” or “the Company”) (NASDAQ:
Jan 25, 2021 11:15 am ET
VYGR EQUITY ALERT: Rosen Law Firm Announces Filing of Federal Securities Class Action Lawsuit Against Voyager Therapeutics, Inc. – VYGR
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1, 2017 and November 9, 2020, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Voyager investors under the federal securities laws.
Jan 22, 2021 11:20 pm ET
Pomerantz Law Firm Announces the Filing of a Class Action against Voyager Therapeutics, Inc. and Certain Officers - VYGR
NEW YORK, Jan. 23, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NASDAQ: VYGR) and certain of its officers.   The class action, filed in United States District Court for the Eastern District of New York, and docketed under 21-cv-00381, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Voyager securities between June 1, 2017 and November 9, 2020, both dates inclusive (the "Class Period"), seeking to recover damages c
Jan 11, 2021 04:03 pm ET
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, has entered into an employment agreement with a newly hired employee that, among other...
Dec 22, 2020 04:17 pm ET
Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program
Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced that the U.S. Food and Drug Administration (FDA) has notified Neurocrine Biosciences (Nasdaq: NBIX) that it has placed a clinical hold on the RESTORE-1 clinical trial of NBIb-1817 (VY-AADC)....
Nov 09, 2020 04:00 pm ET
Voyager Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates
Voyager Therapeutics, Inc. (NASDAQ: VYGR) today reported its third quarter 2020 financial results, program progress and corporate updates. “During the third quarter, we took important steps to advance our lead programs for Parkinson’s disease and...
Oct 21, 2020 08:27 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc. (“Voyager” or the “Company”) (NASDAQ: VYGR).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Oct 12, 2020 04:01 pm ET
Voyager Therapeutics Provides Regulatory Update on VY-HTT01 Program
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced that it has received feedback from the U.S. Food and Drug...
Oct 01, 2020 04:01 pm ET
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, has entered into an employment agreement with a newly hired employee that, among other...
Sep 15, 2020 04:01 pm ET
Voyager Therapeutics Appoints Nancy Vitale to its Board of Directors
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the addition of Nancy Vitale as an independent director to its Board...
Sep 14, 2020 04:30 pm ET
Voyager Therapeutics Appoints Michelle Quinn Smith as Chief Human Resources Officer
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the appointment of Michelle Quinn Smith as Chief Human Resources...
Sep 11, 2020 11:36 am ET
Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor F
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced data from  PD-1101, a Phase Ib open-label, three-year efficacy and safety study, demonstrating that a one-time treatment with investigational...
Sep 03, 2020 04:29 pm ET
Voyager Therapeutics Announces Upcoming Presentations at the International Parkinson and Movement Disorder Society Virtual Congress 2020
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced data presentations at the International Parkinson and Movement...
Aug 10, 2020 07:00 am ET
Voyager Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates
Voyager Therapeutics, Inc. (NASDAQ: VYGR) today reported its second quarter 2020 financial results, program progress and corporate updates. “We anticipate making important progress across our lead programs in the coming months, including...
Aug 03, 2020 04:30 pm ET
Voyager Therapeutics to Report Second Quarter 2020 Financial Results and Participate in Upcoming Investor Conferences
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, will report its second quarter 2020 financial results and corporate updates on Monday,...
Aug 03, 2020 04:01 pm ET
Voyager Therapeutics Provides Update on AbbVie Vectorized Antibody Collaborations
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the termination of its tau and alpha-synuclein vectorized antibody...
Jun 16, 2020 04:01 pm ET
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, has entered into an employment agreement with a newly hired employee that, among other...
May 06, 2020 07:00 am ET
Voyager Therapeutics Announces First Quarter 2020 Financial Results and Corporate Updates
Voyager Therapeutics, Inc. (NASDAQ: VYGR) today reported its first quarter 2020 financial results, program progress and corporate updates. “Our goal is to develop life-changing therapies for people living with severe neurological disease, and...
Apr 29, 2020 07:30 am ET
Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy Virtual 2020 Annual Meeting
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced multiple data presentations at the American Society of Gene and Cell...
Apr 03, 2020 08:30 am ET
Voyager Therapeutics Provides Update on the RESTORE-1 Parkinson’s Disease Trial
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today provided an update on the RESTORE-1 clinical trial of VY-AADC (NBIb-1817) for...
Mar 09, 2020 08:00 am ET
Voyager Therapeutics Announces Cancellation of Presentation and Webcast at the Barclays Global Healthcare Conference
Voyager Therapeutics, Inc. (NASDAQ: VYGR) announced today the cancellation of the Company’s presentation and webcast at the Barclays Global Healthcare Conference, previously scheduled to take place on March 10, 2020 at 4:20 p.m. ET. The change...
Mar 03, 2020 04:01 pm ET
Voyager Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today reported its fourth quarter and full year 2019 financial results, program...
Feb 26, 2020 05:00 pm ET
Voyager Therapeutics to Participate in Upcoming Investor Conferences
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, will webcast management presentations as follows: Cowen 40th Annual Healthcare...
Feb 25, 2020 04:30 pm ET
Voyager Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates on March 3, 2020
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, will report fourth quarter and full year 2019 financial results after market close on...
Nov 06, 2019 06:22 am ET
Voyager Therapeutics Announces Third Quarter 2019 Financial Results and Corporate Highlights
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today reported its third quarter 2019 financial results, program progress and...
Oct 31, 2019 08:00 am ET
Voyager Therapeutics to Present at the Credit Suisse Healthcare Conference
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced a management presentation at the following upcoming investor...
Oct 30, 2019 04:35 pm ET
Voyager Therapeutics to Host Third Quarter 2019 Financial Results and Corporate Highlights Conference Call
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced that it will report its third quarter 2019 financial results and...
Sep 25, 2019 08:00 am ET
Voyager Therapeutics to Present at Upcoming Investor Conferences in October 2019
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced management presentations at the following upcoming investor...
Aug 28, 2019 08:00 am ET
Voyager Therapeutics to Present at Upcoming Investor Conferences in September 2019
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced management presentations at the following upcoming investor...
Aug 09, 2019 07:00 am ET
Voyager Therapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today reported its second quarter 2019 financial results, program progress and...
Aug 05, 2019 04:30 pm ET
Voyager Therapeutics to Host Second Quarter 2019 Financial Results and Corporate Highlights Conference Call
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced that it will report its second quarter 2019 financial results and...
Jul 30, 2019 04:30 pm ET
Voyager Therapeutics to Present at Upcoming Investor Conferences in August 2019
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced management presentations at the upcoming investor conferences:...
Jun 17, 2019 07:30 am ET
Voyager Therapeutics Announces Restructured Gene Therapy Relationship with Sanofi Genzyme and Portfolio Update
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced a restructuring of its gene therapy relationship with Sanofi Genzyme....
Jun 11, 2019 04:30 pm ET
Voyager Therapeutics to Present at the Raymond James Life Sciences & MedTech Conference
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced management’s presentation at the upcoming investor conference:...
May 20, 2019 04:30 pm ET
Voyager Therapeutics Announces Management Updates
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the retirement of Dinah Sah, Ph.D. as Voyager’s chief scientific...
May 07, 2019 07:05 am ET
Voyager Therapeutics Reports First Quarter 2019 Financial Results and Corporate Highlights
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today reported its first quarter 2019 financial results, program progress and...
May 05, 2019 09:05 am ET
Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson’s Disease at the American Academy of Neurology Annual Meeting
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Voyager Therapeutics, Inc. (NASDAQ: VYGR) today announced Phase I trial results for VY-AADC from eight patients with Parkinson’s disease who participated in the open-label trial to evaluate the...
Apr 29, 2019 07:04 am ET
Voyager Therapeutics Announces New Data in Multiple Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced multiple data presentations at the American Society of Gene and Cell...
Apr 15, 2019 12:25 pm ET
Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced multiple data presentations at the American Society of Gene and Cell...
Apr 03, 2019 04:15 pm ET
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c)(4)
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, granted restricted stock units and a non-qualified stock option to Robert Hesslein as...
Apr 02, 2019 04:15 pm ET
Voyager Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today announced management’s presentation at the upcoming investor conference: H.C....
Mar 28, 2019 04:15 pm ET
Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of Neurology
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Voyager Therapeutics, Inc. (NASDAQ: VYGR) today announced the publication of interim results from the Phase 1b trial of VY-AADC, an investigational gene therapy treatment for Parkinson’s disease, in...
Mar 11, 2019 08:00 am ET
MRI Interventions Announces Collaboration with Voyager Therapeutics for the Design, Manufacture and Supply of V-TAG™ Device
MRI Interventions, Inc. (OTCQB:MRIC) a platform neurosurgery company developing products designed to deliver navigation, ablation, deep brain stimulation, aspiration, biopsy and gene therapy today announced a collaboration with Voyager...
Mar 06, 2019 07:50 am ET
Consolidated Research: 2019 Summary Expectations for AMC Entertainment, Spirit Airlines, Voyager Therapeutics, CIT Group, Kaman, and CommVault — Fundamental Analysis, Key Performance Indications
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of AMC Entertainment Holdings, Inc. (NYSE:AMC), Spirit Airlines, Inc....
Feb 26, 2019 04:05 pm ET
Voyager Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today reported its fourth quarter and full year 2018 financial results, provided...
Feb 22, 2019 08:00 am ET
Voyager Therapeutics and AbbVie Announce Collaboration to Develop Vectorized Antibodies to Treat Parkinson’s Disease and Other Synucleinopathies
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, and AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced an...
Feb 22, 2019 07:00 am ET
AbbVie and Voyager Therapeutics Announce Collaboration to Develop Vectorized Antibodies to Treat Parkinson's Disease and Other Synucleinopathies
NORTH CHICAGO, Ill. and CAMBRIDGE, Mass., Feb. 22, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Voyager Therapeutics, Inc. (Nasdaq: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced an exclusive, global strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed at pathological species of alpha-synuclein for the potential treatment of Parkinson's disease and other diseases (synucleinopathies) characterized by the abnorma
Feb 19, 2019 08:00 am ET
Voyager Therapeutics to Present at Upcoming Investor Conferences
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced management’s presentation at the upcoming investor conferences: SVB...
Feb 18, 2019 08:00 am ET
Voyager Therapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights Conference Call
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced plans to host its fourth quarter and full year 2018 financial results...
Jan 29, 2019 07:00 am ET
Neurocrine Biosciences and Voyager Therapeutics Form Strategic Development and Commercialization Collaboration for Parkinson’s Disease and Friedreich’s Ataxia
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Voyager Therapeutics, Inc. (NASDAQ: VYGR), today announced the formation of a strategic collaboration focused on the development and commercialization of Voyager’s gene therapy programs, VY-AADC for...
Jan 22, 2019 07:05 am ET
Voyager Therapeutics Appoints Robert Hesslein as General Counsel
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the appointment of Robert Hesslein as general counsel. Mr. Hesslein’s...
Jan 16, 2019 07:40 am ET
Consolidated Research: 2019 Summary Expectations for Southern, Exelon, PriceSmart, Five Prime Therapeutics, Digi International, and Voyager Therapeutics — Fundamental Analysis, Key Performance Indicat
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Southern Company (NYSE:SO), Exelon Corporation (NYSE:EXC), PriceSmart,...
Jan 15, 2019 07:03 am ET
Voyager Therapeutics to Appoint Omar Khwaja, M.D., Ph.D., as Chief Medical Officer
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the appointment of Omar Khwaja, M.D., Ph.D., as chief medical officer....
Jan 07, 2019 07:07 am ET
Voyager Therapeutics Provides Updates for VY-AADC Clinical Program for Parkinson’s Disease
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced an update to its VY-AADC clinical program for Parkinson’s disease. In...
Dec 17, 2018 07:10 am ET
Voyager Therapeutics Joins Michael J. Fox Foundation Initiatives and Education Campaigns to Accelerate the Development of New therapies and a Cure for Parkinson’s Disease
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced joining multiple partnerships with The Michael J. Fox Foundation for...
Dec 10, 2018 07:10 am ET
Voyager Therapeutics Announces First Patient Dosed in RESTORE-1, a Phase 2 Trial of VY-AADC Gene Therapy for the Treatment of Parkinson’s Disease
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced dosing of the first patient in RESTORE-1, a Phase 2, randomized,...
Nov 29, 2018 07:04 am ET
Voyager Therapeutics Enters into Strategic Manufacturing Collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced that it has entered into collaborations with Brammer Bio (Brammer) and...
Nov 23, 2018 08:10 am ET
Report: Exploring Fundamental Drivers Behind Graphic Packaging Holding, QEP Resources, Inogen, CytRx, Voyager Therapeutics, and Daily Journal Corp. (S.C.) — New Horizons, Emerging Trends, and Upcoming
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Graphic Packaging Holding Company (NYSE:GPK), QEP Resources, Inc....
Nov 19, 2018 04:21 pm ET
Voyager Therapeutics to Present at the Evercore ISI Healthcare Conference
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today announced management’s presentation at the upcoming investor conference:...
Nov 07, 2018 04:10 pm ET
Voyager Therapeutics Announces Positive Longer-Term Data for VY-AADC for Parkinson’s Disease
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced positive longer-term results from the open-label, dose-escalating...
Nov 07, 2018 04:10 pm ET
Voyager Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Highlights
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today reported its third quarter 2018 results, recent progress and corporate updates...
Oct 31, 2018 06:30 am ET
Voyager Therapeutics to Host Third Quarter 2018 Financial Results and Corporate Highlights Conference Call
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced its third quarter 2018 financial results and corporate highlights...
Oct 16, 2018 07:03 am ET
Voyager Therapeutics Announces Preclinical Data for Huntington’s Disease and Amyotrophic Lateral Sclerosis Programs at the Congress of the European Society of Gene and Cell Therapy
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced data presentations at the Congress of the European Society of Gene and...
Aug 28, 2018 11:53 am ET
Voyager Therapeutics to Present at Investor Conferences in September
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced management presentations at the upcoming investor conferences: Wells Fargo...
Aug 07, 2018 04:07 pm ET
Voyager Therapeutics Announces Second Quarter 2018 Financial Results and Corporate Highlights
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today reported its second quarter 2018 results, recent progress and corporate updates...
Aug 02, 2018 08:26 am ET
Voyager Therapeutics to Present at Investor Conferences in August
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced management presentations at the upcoming investor conferences: Canaccord Genuity...
Jul 31, 2018 04:59 pm ET
Voyager Therapeutics Announces Second Quarter 2018 Financial Results and Corporate Highlights Conference Call
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing treatments for severe neurological diseases, today announced its second quarter 2018 financial results and corporate highlights conference call...
Jul 17, 2018 07:04 am ET
Voyager Therapeutics Receives FDA Guidance on Development Path for VY-AADC for Parkinson’s Disease and Provides Clinical Update
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today announced feedback from a Type C meeting with the U.S. Food and Drug...
Jun 28, 2018 04:30 pm ET
Voyager Therapeutics Appoints Andre Turenne as President and Chief Executive Officer
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today announced the appointment of G. Andre Turenne as president and chief executive...
Jun 21, 2018 07:03 am ET
Voyager Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted for VY-AADC for the Treatment of Parkinson’s Disease
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative...
May 29, 2018 04:30 pm ET
Voyager Therapeutics Announces Management Change
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today announced that Jane Henderson, Voyager’s chief financial officer and senior vice...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.